# US 2021/0330787 A1 · Antigen Binding Proteins That Bind PD-L1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330787 A1
- Document ID: US20210330787A1
- Status: Published application
- Kind: A1
- Application number: 17/306,395
- Filed: 2021-05-03
- Published: 2021-10-28
- Earliest claimed: 2012-05-31
- Assignees: Sorrento Therapeutics, Inc.
- Applicants: Sorrento Therapeutics, Inc.
- Inventors: Heyue Zhou; Randy Gastwirt; Barbara A. Swanson; John Dixon Gray; Gunnar F. Kaufmann
- Web page: https://patentgrep.com/patent/US20210330787A1

## CPC

- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2121/00: Preparations for use in therapy
- C07K 2317/21: from primates, e.g. man
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO: 221; and comprising a light chain variable domain comprising CDRs as set forth in the light chain variable domain amino acid sequence of SEQ ID NO: 222.

### Claim 15 (depends on 14)

The anti-PD-L1 antibody of claim 14, wherein the antibody is an IgG.

### Claim 16 (depends on 14)

The anti-PD-L1 antibody, or antigen binding fragment thereof, of claim 14, wherein the heavy chain variable domain comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 221, and the light chain variable domain comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 222.

### Claim 17 (depends on 14)

The anti-PD-L1 antibody, or antigen binding fragment thereof, of claim 14, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 221, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 222.

### Claim 18 (depends on 14)

The antigen binding fragment of the anti-PD-L1 antibody of claim 14, wherein the fragment is a Fab fragment.

### Claim 19 (depends on 14)

The antigen binding fragment of the anti-PD-L1 antibody of claim 14, wherein the fragment is a single chain human antibody.

### Claim 20 (depends on 14)

A pharmaceutical composition comprising the anti-PD-L1 antibody, or antigen-binding fragment thereof, of claim 14, and a pharmaceutically acceptable excipient.

### Claim 21 (depends on 14)

A method of treating a human subject having cancer comprising administering an effective amount of the anti-PD-L1 antibody, or antigen binding fragment thereof, of claim 14.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is selected from the group consisting of ovarian cancer, colon cancer, breast cancer, lung cancer, myeloma, a neuroblastic-derived CNS tumor, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, a B-cell derived lymphoma, a T-cell derived lymphoma, skin cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck cancer, pancreatic cancer, bladder cancer, bone cancer, cartilage cancer, liver cancer, lymph node cancer, nervous tissue cancer, skeletal muscle cancer, spinal cord cancer, spleen cancer, brain cancer, colorectal cancer, thyroid cancer, prostate cancer, vaginal cancer, kidney cancer, thymus cancer, thyroid cancer, stomach cancer, cancer of the urogenital tract, cancer of the ureter, cancer of the urethra, cancer of the uterus, cancer of the testes, and a mast cell derived tumor.

### Claim 23 (depends on 18)

A method for treating a human subject having cancer, said method comprising administering an effective amount of the fully human antibody Fab fragment of claim 18 to the human subject.

### Claim 24 (depends on 19)

A method for treating a human subject having cancer, said method comprising administering an effective amount of the single chain human antibody of claim 19 to the human subject.

### Claim 25

A nucleic acid encoding
a. an antibody heavy chain comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 221, and
b. an antibody light chain comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 222.

### Claim 26 (depends on 25)

The nucleic acid of claim 25, wherein the heavy chain variable domain comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 221, and the light chain variable domain comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 222.

### Claim 27 (depends on 25)

The nucleic acid of claim 25, wherein the antibody heavy chain comprises a heavy chain variable region having an amino acid sequence of SEQ ID NO: 221, and the antibody light chain comprises a light chain variable region having an amino acid sequence of SEQ ID NO: 222.

### Claim 28 (depends on 25)

The nucleic acid of claim 25, wherein the antibody is an IgG, a Fab fragment, or a single chain human antibody.

### Claim 29 (depends on 25)

An expression vector comprising a promoter operably linked to the nucleic acid of claim 25.

### Claim 30 (depends on 25)

A host cell harboring the nucleic acid of claim 25 or an expression vector comprising a promoter operably linked to the nucleic acid of claim 25.

### Claim 31 (depends on 30)

A method for preparing a recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising culturing a population of the host cell of claim 30 under conditions suitable for expressing the recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof.

### Claim 32 (depends on 31)

The method of claim 31, further comprising recovering from the host cell population the expressed recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof.
